Compare HCWB & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | AIDX |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 2.9M |
| IPO Year | 2021 | 2025 |
| Metric | HCWB | AIDX |
|---|---|---|
| Price | $0.99 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.2K | ★ 208.0K |
| Earning Date | 11-24-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.48 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,099,750.00 | $2,045,133.00 |
| Revenue This Year | $12,215.61 | $44.20 |
| Revenue Next Year | N/A | $95.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.86 | $0.18 |
| 52 Week High | $23.94 | $18.96 |
| Indicator | HCWB | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 33.51 |
| Support Level | $0.86 | N/A |
| Resistance Level | $1.28 | $0.27 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 18.49 | 34.53 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.